National Broker Sales Trainer
Devoted Health- Full Time
- Entry Level & New Grad
Corcept is a leader in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). With over 1,000 proprietary cortisol modulators discovered and FDA approval of Korlym® (mifepristone) for hypercortisolism (Cushing’s syndrome), Corcept is dedicated to advancing the possibilities of cortisol modulation for treating serious diseases. The National Field Training Manager will be responsible for providing initial disease state and product training for newly hired Clinical Specialists (CSs) and ongoing field training for the Salesforce. This role involves observing CS activities, deploying training curriculum for new materials and product updates, and assisting in the development and implementation of training initiatives for the Commercial organization.
Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). Corcept has discovered more than 1,000 selective proprietary cortisol modulators and received FDA approval of Korlym® (mifepristone) in 2012, the first approved treatment for hypercortisolism (Cushing’s syndrome). The company's team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases, with more than 30 ongoing studies across a wide range of disease areas including endocrinology, oncology, metabolism, and neurology. Corcept is dedicated to advancing the possibilities of cortisol modulation, representing a fundamental shift in the understanding and treatment of disease.
Develops cortisol modulators for medical conditions
Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.